By Daniella Parra Lisata Therapeutics (Nasdaq: LSTA), said it has fully enrolled the pancreatic cancer cohort for the CENDIFOX trial. The company said it evaluates certepetide with FOLFIRINOX therapies in pancreatic, colon, and appendiceal cancers and the trial is being...

By Karen Roman Aktis Oncology said it appointed Dr. Ken Herrmann to the Board of Directors. Dr. Herrmann specializes in nuclear medicine and has over a decade of experience in clinical investigation, the company said. “Ken’s joining us on the...

By Karen Roman Vivani Medical, Inc. (Nasdaq: VANI) said the FDA allowed the beginning of a phase 1 for the clinical trial of NPM-119, its long-term mini-implant for type-2 diabetes treatment. Vivani is also advancing in the development of NPM-115...

By Daniella Parra Imperium Health and DecisionRx are teaming up to provide free Medication Therapy Optimization (MTO) to Medicare patients in Imperium’s Accountable Care Organizations (ACOs), the company said. This program aims to enhance patient outcomes and cut healthcare costs...

By Karen Roman MOBILion Systems announced it is presenting the latest features of its mass spectrometry platform, MOBIE EyeOn 2.3, at the 72nd American Society for Mass Spectrometry (ASMS) Conference in California. The latest software introduces new capabilities and streamlines...

By Daniella Parra Sparrow Pharmaceuticals said its HSD-1 inhibitor, clofutriben (SPI-62), normalized urine free cortisol in over 60% of patients with endogenous Cushing’s syndrome without significantly lowering serum cortisol, minimizing the risk of adrenal insufficiency. Traditional EnCS treatments require careful...

By Daniella Parra Creyon Bio, Inc. said it is using AI to engineer treatments for rare and common diseases. The platform’s ability to predict and mitigate safety concerns signifies a promising advancement as they customized a treatment within a year,...

By Karen Roman FIGS, Inc. (NYSE: FIGS), a global healthcare apparel brand, said net revenue was at the upper end of expectations and exceeded the outlook in the first quarter. The company reported a 0.8% decrease year over year in...

By Daniella Parra Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company, said its net loss was $5.4 million for the three months ended March 31, compared to $6.2 million in 2023. The company said an experimental drug to improve...

  By Daniella Parra Creyon Bio, Inc. and Cajal Neuroscience have teamed up to develop therapies for neurodegenerative diseases, they said. The companies aim to accelerate the development of treatments for common neurodegenerative disorders, engineering medicines using human data and...